Romidepsin
![ISTODAX (Romidepsin) Must Be Fetus [See Use in Specific Populations (8.1)]](http://data.docslib.org/img/264x/07713f2025057230b286386fcd4067c8.webp)
Top View
- (CMS) Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions First Quarter 2021 Coding Cycle for Drug and Biological Products
- Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
- Romidepsin: Istodax
- Cancer Drug Costs for a Month of Treatment at Initial Food
- Cell Lymphoma (CTCL) in Patients Who Have the Fetus and to Avoid Pregnancy While Receiving ISTODAX (5.5, 8.1)
- And Effective in Patients with Relapsed Or Refractory T-Cell 3 Lymphoma: Results of a Translational Phase I Dose-Escalation 4 Study
- 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
- Immediate Management of an Extravasation
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Romidepsin in the Treatment of Hematologic Malignancies
- FDA Approval: Belinostat for the Treatment of Patients with Relapsed Or Refractory
- Table S1. Recent Registered Clinical Trials on Phenolic Compounds with Epigenetic Mechanisms in Different Cancers Alone and in Co-Treatment
- Angioimmunoblastic T-Cell Lymphoma
- Preliminary Results of Tranilast Treatment for Patients with Advanced Castration-Resistant Prostate Cancer
- Emerging Drugs for Prostate Cancer
- Mechanisms of Temozolomide Resistance in Glioblastoma - a Comprehensive Review
- A Phase I Study of Romidepsin and Ifosfamide, Carboplatin, Etoposide
- The State-Of-The-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies